Silexion Therapeutics Completes 1-for-10 Reverse Stock Split and Adjusts Warrants
SLXN is trading near its 52-week low of $2.31 (82% below the low) on light trading volume (0.2× avg).
Summary
Silexion Therapeutics has completed its 1-for-10 reverse stock split, effective May 29, 2026, and adjusted its outstanding warrants accordingly.
Key Events · Corporate Governance and Compliance · SLXN
-
Reverse Stock Split Completed
The 1-for-10 reverse stock split became effective on May 29, 2026, reducing the number of outstanding shares and increasing the par value from $0.0135 to $0.135 per share.
-
Warrant Terms Adjusted
Outstanding warrants were adjusted, with each pre-split warrant now exercisable for 1/10th of an ordinary share and the exercise price increasing tenfold to $15,525.00 per post-split share.
-
Nasdaq Compliance Effort
This action was primarily undertaken to meet Nasdaq's minimum bid price requirement, following shareholder approval on May 5, 2026, and is a necessary step for the company's continued listing.
Analysis · SLXN · Life Sciences
This 8-K confirms the formal execution of the previously approved 1-for-10 reverse stock split, which became effective on May 29, 2026. The split was a critical step for Silexion Therapeutics to meet Nasdaq's minimum bid price requirement and enable future capital raises, given its ongoing financial distress and going concern warnings. The company is currently trading near its 52-week low, highlighting the challenging market conditions. The filing also details the proportional adjustments made to the company's outstanding warrants, including a tenfold increase in their exercise price.
At the time of this filing, SLXN was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8M. The 52-week trading range was $2.31 to $223.60. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.